Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Hutchmed
HMPL-760 is a reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), including the wild-type enzyme and the C481S mutant form. By blocking BTK it inhibits B-cell antigen receptor signaling and the growth of malignant B cells. It is being studied in relapsed or refractory diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07409428 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | HCM |
| NCT06601504 | Phase 2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →